CalciMedica公司宣布，其候选药物Auxora的临床开发工作有望继续推进。这一决定是在美国食品药品监督管理局（FDA）完成了对Kourage临床试验中期安全性数据的审查之后作出的。
此次审查为Auxora的后续开发路径提供了关键支持。公司表示，将根据FDA的反馈，继续推进该药物的临床研究计划。
CalciMedica公司宣布，其候选药物Auxora的临床开发工作有望继续推进。这一决定是在美国食品药品监督管理局（FDA）完成了对Kourage临床试验中期安全性数据的审查之后作出的。
此次审查为Auxora的后续开发路径提供了关键支持。公司表示，将根据FDA的反馈，继续推进该药物的临床研究计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.